Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The interaction between Heat shock 70 kDa protein (Hsp70) and Bcl-2-associated athanogene 1 (BAG-1) is a critical regulatory node in the cellular protein folding machinery (UniProt: P0DMV8, Q99933). Hsp70 is a molecular chaperone that assists in protein folding and prevents aggregation, while BAG-1 acts as a nucleotide exchange factor (NEF) that binds to the Hsp70 nucleotide-binding domain (NBD) (PubMed: 10551805). This interaction stimulates the release of ADP from Hsp70, facilitating the binding of ATP and the subsequent release of client proteins to complete the chaperone cycle (PubMed: 11248689). In many cancers, both Hsp70 and BAG-1 are overexpressed, leading to the stabilization of oncogenic proteins such as Akt, Raf-1, and various steroid receptors, which promote cell survival and proliferation (PubMed: 15671246). Consequently, the Hsp70–BAG-1 protein-protein interaction (PPI) has emerged as a promising therapeutic target for inducing proteotoxicity in malignant cells (PubMed: 23934152). Small molecule inhibitors, such as the allosteric inhibitor JG-98 and Thioflavin S derivatives, have been developed to disrupt this interface, leading to the degradation of client proteins and the induction of apoptosis (PubMed: 25852015).
Inhibition of the protein-protein interaction between the Hsp70 nucleotide-binding domain and the BAG domain of BAG-1, preventing nucleotide exchange and disrupting the chaperone-mediated stabilization of oncogenic client proteins (PubMed: 23934152).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Heat shock 70 kDa protein–Bcl-2-associated athanogene 1 protein-protein interaction (Hsp70–BAG-1 PPI).